A detailed history of Redmile Group, LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Redmile Group, LLC holds 97,116 shares of CYTK stock, worth $4.84 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares
97,116
Previous 111,867 13.19%
Holding current value
$4.84 Million
Previous $6.06 Million 15.4%
% of portfolio
0.34%
Previous 0.4%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$51.22 - $60.16 $755,546 - $887,420
-14,751 Reduced 13.19%
97,116 $5.13 Million
Q2 2024

Aug 14, 2024

SELL
$47.86 - $75.05 $2.38 Million - $3.73 Million
-49,733 Reduced 30.78%
111,867 $6.06 Million
Q1 2024

May 15, 2024

BUY
$63.75 - $108.06 $10.3 Million - $17.5 Million
161,600 New
161,600 $11.3 Million

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.69B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.